Welcome to our dedicated page for Innate Pharma Sa news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma Sa stock.
Innate Pharma S.A. (IPHA) news covers the company’s progress as a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. As a dual-listed issuer on Euronext Paris (IPH) and Nasdaq (IPHA), Innate Pharma regularly publishes regulatory and corporate updates that are relevant to investors following immuno-oncology and antibody-based therapeutics.
News about Innate Pharma frequently highlights developments across its antibody-engineering and ANKET® (Antibody-based NK cell Engager Therapeutics) platform. Company releases describe clinical and regulatory milestones for key assets such as IPH4502, a differentiated Nectin-4 ADC in solid tumors; lacutamab, a first-in-class anti-KIR3DL2 monoclonal antibody in cutaneous and peripheral T cell lymphomas; and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer.
Investors can expect updates on clinical trial progress, including Phase 1, Phase 2 and Phase 3 studies, regulatory designations for pipeline assets, and collaboration news involving partners such as Sanofi and AstraZeneca. Innate Pharma’s news flow also includes financial communications, such as business updates, financial results, financial calendars, and regulatory disclosures on the number of shares outstanding and voting rights under French market rules.
This news page aggregates these company communications in one place, making it easier to follow Innate Pharma’s clinical pipeline evolution, partnership activities and key corporate events. Readers interested in immuno-oncology, antibody-drug conjugates, NK cell engagers and collaboration-driven biotech models can use this feed to monitor how Innate Pharma reports its progress over time.
Innate Pharma reported its Q3 2024 business update with several key developments. Jonathan Dickinson was appointed as CEO and Chairman of the Executive Board. The company received encouraging FDA feedback on lacutamab's regulatory pathway and FDA clearance for IPH4502, a Nectin-4 ADC for solid tumors. The cash position stood at €96.4 million as of September 30, 2024, with runway until end of 2025. Revenue for the first nine months of 2024 was €10.2 million, compared to €36.5 million in the same period of 2023. Multiple clinical trials are progressing, including TELLOMAK Phase 2 for lacutamab and various ANKET® platform developments.
Innate Pharma announced new preclinical data presentations at the SITC Annual Meeting 2024, featuring two key developments: IPH6501, a tetra-specific NK cell engager targeting CD20 for B cell Non-Hodgkin Lymphoma, and IPH4502, an antibody-drug conjugate (ADC) targeting Nectin-4. The presentations include an oral session on NK Cells and Innate Immunity, chaired by CSO Eric Vivier, and two poster presentations scheduled for November 8-9, 2024, in Houston, Texas. Additionally, related research on the Nectin-4 targeting ADC was presented at the PEGS Europe Summit.
Innate Pharma (Nasdaq: IPHA) has announced a conference call and webcast scheduled for Wednesday, November 13, 2024, at 2 p.m. CET / 8 a.m. ET to discuss third quarter 2024 results and business updates. Key executives participating include CEO Jonathan Dickinson, CMO Sonia Quaratino, COO Yannis Morel, CFO Frédéric Lombard, and EVP US Operations Arvind Sood. The live webcast will be accessible via a dedicated link, with a telephone option available for participants. A replay will be available on the company website for 90 days after the event.
Innate Pharma (Nasdaq: IPHA) has announced its upcoming participation in several major healthcare investor conferences. The company's executive team will attend five prestigious events between November and December 2024, including the Stifel Healthcare Conference and Jefferies London Healthcare Conference in mid-November, followed by the Wolfe Healthcare Conference in New York. In early December, the team will participate in the 7th Annual Evercore ISI HealthCONx Conference and Citi's Global Healthcare Conference, both taking place in Miami.
Innate Pharma has appointed Jonathan Dickinson as its new Chief Executive Officer and Chairman of the Executive Board, effective November 1, 2024. Dickinson, who most recently served as Executive Vice President and General Manager, Europe at Incyte, brings extensive experience from leadership roles in biotech and big pharma. He succeeds Hervé Brailly, co-founder and interim CEO, who will stay on in an advisory role to ensure a smooth transition.
Dickinson's career includes senior positions at ARIAD Pharmaceuticals, Bristol-Myers Squibb, and a 13-year tenure at Hoffmann-La Roche. He holds a Bachelor of Science in Genetics and an MBA from the University of Nottingham. The appointment aims to drive the advancement of Innate Pharma's immuno-oncology pipeline and position the company for future growth.
Innate Pharma is set to co-host a scientific symposium titled 'Next Generation Immunotherapy Discoveries' with the Icahn School of Medicine at Mount Sinai on October 3, 2024. The event, part of Innate Pharma's 25th anniversary celebration, will be held in a hybrid format in New York City and online from 10:00 a.m. to 5:30 p.m. EDT.
The symposium will showcase the latest advances in immunotherapy, featuring presentations from key opinion leaders in the field. Participants will have the opportunity to engage with speakers during Q&A sessions. Prior to the symposium, Innate Pharma will host an Investor and Analyst Meeting from 8:30 a.m. to 9:30 a.m. EDT to provide an overview of the company's therapeutic innovations.
The event will include speakers from prestigious institutions such as Memorial Sloan Kettering Cancer Center, Harvard Medical School, and UCLA Jonsson Comprehensive Cancer Center, among others.
Innate Pharma announced FDA clearance of its IND application for IPH4502, a novel topoisomerase I inhibitor antibody drug conjugate (ADC) targeting Nectin-4 in solid tumors. The company plans to initiate a Phase 1 clinical study in the coming months. The study will be an open-label, multi-center trial assessing the safety, tolerability, and preliminary efficacy of IPH4502 as a single agent in advanced solid tumors known to express Nectin-4, including urothelial carcinoma, non-small cell lung, breast, ovarian, gastric and colorectal cancers.
The study will include a Part 1 Dose Escalation and a Part 2 Dose Optimization. This marks Innate's first ADC program to enter clinical trials, representing a significant milestone for the company.
Innate Pharma reported its H1 2024 business update and financial results. Key highlights include:
- Positive Phase 2 results for lacutamab in mycosis fungoides presented at ASCO 2024
- NK-Cell engager SAR443579/IPH6101 advanced to Phase 2 and initiated front-line AML Phase 1/2 combination study
- IPH45 ADC progressing towards Phase 1 in H2 2024
- Cash position of €102.1 million as of June 30, 2024
- Revenue decreased to €12.3 million in H1 2024 from €40.2 million in H1 2023
- Operating expenses decreased slightly to €38.7 million in H1 2024 from €40.6 million in H1 2023
- R&D expenses decreased to €29.1 million in H1 2024 from €31.5 million in H1 2023
The company continues to advance its pipeline and maintains a cash runway until end of 2025.
Innate Pharma SA announced interim results from AstraZeneca's NeoCOAST-2 Phase 2 study presented at the 2024 World Conference on Lung Cancer. The study evaluates neoadjuvant durvalumab alone or combined with novel agents and chemotherapy in resectable, early-stage non-small cell lung cancer (NSCLC). Preliminary data from Arm 2 showed that monalizumab added to durvalumab plus platinum-based chemotherapy induced a pathological complete response rate of 26.7% and a major pathological response rate of 53.3%, numerically higher than the approved regimen. The treatment demonstrated a manageable safety profile with no impact on surgical rate. Innate Pharma's Chief Medical Officer expressed excitement about the potential of extending durvalumab's clinical benefit with monalizumab in NSCLC patients.
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) has announced a conference call and webcast scheduled for Thursday, September 12, 2024, at 2 p.m. CEST / 8 a.m. EDT. The event will provide an update on the company's business progress during the first half of 2024. Key participants will include CEO Hervé Brailly, CMO Sonia Quaratino, COO Yannis Morel, CFO Frédéric Lombard, and EVP and President of US Operations Arvind Sood.
Investors and interested parties can join the live webcast or participate via telephone. A replay of the webcast will be available on the company's website for 90 days following the event. This announcement suggests that Innate Pharma is preparing to share important financial results and business updates with its stakeholders.
FAQ
What is the current stock price of Innate Pharma Sa (IPHA)?
What is the market cap of Innate Pharma Sa (IPHA)?
